Galectin Therapeutics Total Current Liabilities

The latest total current liabilities for GALT is $150M as of June 2026. That compares with $11M in the prior-year period — up 1307.3% year over year. Investors often review this figure alongside Galectin Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GALT's total current liabilities moved from $11M to $150M — a 1307.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Galectin Therapeutics's operating scale or balance-sheet position.

A total current liabilities figure of $150M for GALT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GALT's total current liabilities ($150M), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Galectin Therapeutics's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.